$1.39
2.80% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US87166L1008
Symbol
SYBX
Sector
Industry

Synlogic Inc Stock price

$1.39
-0.03 2.11% 1M
-0.21 13.13% 6M
-2.46 63.90% YTD
-0.58 29.44% 1Y
-38.21 96.49% 3Y
-30.41 95.63% 5Y
-738.86 99.81% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.04 2.80%
ISIN
US87166L1008
Symbol
SYBX
Sector
Industry

Key metrics

Market capitalization $16.26m
Enterprise Value $-3.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.09
EV/Sales (TTM) EV/Sales -1.13
P/S ratio (TTM) P/S ratio 5.85
P/B ratio (TTM) P/B ratio 1.24
Revenue growth (TTM) Revenue growth 292.23%
Revenue (TTM) Revenue $2.78m
EBIT (operating result TTM) EBIT $-25.03m
Free Cash Flow (TTM) Free Cash Flow $-36.66m
Cash position $19.39m
EPS (TTM) EPS $-4.15
P/E forward negative
Short interest 1.31%
Show more

Is Synlogic Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Synlogic Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Synlogic Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Synlogic Inc:

Hold
100%

Financial data from Synlogic Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2.78 2.78
292% 292%
100%
- Direct Costs 2.57 2.57
53% 53%
92%
0.21 0.21
104% 104%
8%
- Selling and Administrative Expenses 4.12 4.12
35% 35%
148%
- Research and Development Expense 19 19
59% 59%
667%
-22 -22
60% 60%
-808%
- Depreciation and Amortization 2.57 2.57
53% 53%
92%
EBIT (Operating Income) EBIT -25 -25
60% 60%
-900%
Net Profit -44 -44
26% 26%
-1,590%

In millions USD.

Don't miss a Thing! We will send you all news about Synlogic Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Synlogic Inc Stock News

Neutral
GlobeNewsWire
14 days ago
WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update.
Neutral
GlobeNewsWire
4 months ago
WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update.

Company Profile

Synlogic, Inc. is a clinical-stage biopharmaceutical company. It engages in drug discovery and development of synthetic biotic medicines. The firm focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Head office United States
CEO Antoine Awad
Employees 6
Founded 2017
Website www.synlogictx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today